Price Tussle Starts Over $371,000 Breakthrough Cancer Drug

Bookmark
(Bloomberg) -- Novartis AG’s breakthrough cancer drug Kymriah has been approved in Europe. Now comes the debate about its hefty cost.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.